Breathe Well Live Well
|
For Severe Asthma, Most Surveyed U.S. Payers Would Reimburse a Novel …
PR Newswire (press release) Surveyed U.S. and European pulmonologists agree that reduction in rate of exacerbations is the attribute that most influences prescribing decisions in moderate to severe asthma. Clinical data and the opinions of interviewed thought leaders indicate … |
View full post on asthma – Google News
|
For Severe Asthma, Most Surveyed U.S. Payers Would Reimburse a Novel …
MarketWatch Efficacy versus price: Results of a conjoint analysis indicate that in severe asthma, U.S. pulmonologists are willing to prescribe a novel therapy with strong efficacy in reductions in exacerbations and oral corticosteroid dose even if that drug … |
View full post on asthma – Google News